Janssen Pharmaceutica Nv

Vanderbilt University

Beerse Pharmaceutica Nv

Susana Conde-Ceide

José Manuel Bartolomé-Nebreda

Gregor James MacDonald

Craig William Lindsley

P Jeffrey Conn

Shaun R Stauffer

Michiel Luc Maria Van Gool

María Luz Martín-Martín

Carrie K Jones

Han Min Tong

José Ignacio Andrés-Gil

Michiel Luc Van Gool

Jose Manuel Bartolome-Nebreda

Andrés Avelino Trabanco-Suárez

Gary John Tresadern

Manuel Jesús Alcázar-Vaca

Óscar Delgado-González

Sergio-Alvar Alonso-de Diego

Joaquin Pastor-Fernández

Gregor James Macdonald

Greta Constantia Peter Vanhoof

Jason Manka

Ya Zhou

Miguel Angel Pena-Piñón

Jon Jacobs

Joaquin Pastor-Fernandez

Greta Constantia Vanhoof

Oscar Delgado-Gonzalez

Maria Luz Martin-Martin

Manuel Jesus Alcazar Vaca

Johan Erwin Edmond Weerts

Carina Leys

Francisca Delgado-Jiménez

Stijn Wuyts

Gregor McDonald

José Manuel Bartolome-Nebreda

Kelly Ann Swinney

Chrysa Malosh

Laurent Christian L Leclercq

Gregor Macdonald

Eric S Dawson

Francisca Delgado-Jimenez

Laurent Christian Leclercq

Sergio-Alvar Alonso-De Diego

Johan Erwin Weerts

José Ignacio ANDRÉS-Gil

ÓScar Delgado-GONZÁLEZ

Andres Avelino Trabanco-Suarez

Luc Maria Michiel

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula I as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ('mGluR2'). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ('mGluR2'). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

6,7-dihydropyrazolo[1,5-&#x3b1;]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor sub-type 2 ('mGluR2') of Formula I:  The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such com-pounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ('mGluR2'). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

[object Object]

Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors

The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Inhibitors of phosphodiesterase 10 enzyme

In one aspect, the invention relates to substituted pyrazolo[1,5-a]pyrazines analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators

In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ('mGluR5'); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors

The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ('mGluR5') and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

Bicyclic thiazoles as allosteric modulators of mGluR5 receptors

In one aspect, the invention relates to substituted bicyclic alkoxy pyrazole analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors

In one aspect, the invention relates to imidazopyrimidin-5(6H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases

In one aspect, the invention relates to naphthyridinone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Naphthyridinone analogs as mGluR5 positive allosteric modulators

The present invention relates to novel imidazo[1,2-]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors

Growing community of inventors

Toledo, Spain

Susana Conde-Ceide